While cytokine storm develops in a minority of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, novel treatment approaches are desperately needed for those in whom it does. Tocilizumab, an interleukin-6 receptor antibody, has been utilized for the treatment of cytokine storm in a number of severe inflammatory conditions, including in patients with severe coronavirus disease 2019 (COVID-19). Here, we present the first published case utilizing this therapy in a patient with underlying immunodeficiency. Our patient with aplastic anemia developed cytokine storm due to COVID-19 manifested by fever, severe hypoxia, pulmonary infiltrates, and elevated inflammatory markers. Following treatment with tocilizumab, cytokine storm resolved, and the patient was ultimately safely discharged from the hospital.
【저자키워드】 COVID-19, SARS-CoV-2, Cytokine storm, Tocilizumab, Aplastic anemia, 【초록키워드】 Treatment, Anemia, coronavirus, therapy, antibody, hospital, Infection, immunodeficiency, inflammatory markers, Fever, Patient, interleukin-6 receptor, acute respiratory syndrome, severe coronavirus disease, pulmonary infiltrates, inflammatory conditions, while, severe hypoxia, develop, the patient, elevated, discharged, manifested, resolved, treatment approach, treatment with tocilizumab,